Results 11 to 20 of about 694 (96)

Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors

Clinical and Experimental Gastroenterology, 2023
Prapassorn Thirasastr, Neeta Somaiah Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Neeta Somaiah, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson ...
Neeta Somaiah, Prapassorn Thirasastr
exaly   +2 more sources

Negative outcomes associated with tyrosine kinase inhibitors during management of gastrointestinal stromal tumors: examination of data from the FDA adverse event reporting system [PDF]

Frontiers in Oncology
BackgroundSince the approval of Tyrosine kinase inhibitors (TKIs) in gastrointestinal stromal tumors (GISTs), the survival of patients with metastatic GISTs have been remarkably improved. But clinically, the adverse effects (AEs) are the major barrier to
Yuxuan Ma, Yuxuan Ma, Ahui Fan, Yuhao Wang, Yuhao Wang, Shenhui Xu, Xin Liu, Xin Liu, Jianjun Yang   +8 more
doaj   +2 more sources

A case report of advanced small intestinal stromal tumor with KIT gene mutation and BRCA2 deletion after multi-line treatments [PDF]

Frontiers in Oncology
This study reports a 40-year-old male with small intestinal stromal tumor (SIST). After initial surgery and adjuvant imatinib, the tumor recurred. The patient then received multiple rounds of treatment with targeted drugs and surgical interventions ...
Shiyun Cui, Shiyun Cui, Lei Fan, Lei Fan, Yu Bai, Xinnan Sun, Yucheng Cai, Jingqi Dai, Ting Wang, Chongqi Sun, Rong Wang, Lianke Liu   +11 more
doaj   +2 more sources

Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor After Imatinib Resistance [PDF]

Pharmaceutics
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, primarily driven by activating mutations in KIT (CD117) and platelet-derived growth factor receptor alpha (PDGFRA). The introduction of tyrosine
Xian-Hao Xiao, Qian-Shi Zhang, Ji-Yuan Hu, Yin-Xu Zhang, He Song   +4 more
doaj   +2 more sources

Correction: Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS) [PDF]

Frontiers in Pharmacology
Xinzhen Che, Yong Zhu
doaj   +2 more sources

Pharmacokinetics and Safety of Ripretinib in Participants with Hepatic Impairment: A Phase 1 Study [PDF]

Advances in Therapy
Rodrigo Ruiz-Soto
exaly   +2 more sources

Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience

Frontiers in Oncology, 2022
BackgroundRipretinib was recently approved for the fourth-line targeted therapy for advanced gastrointestinal stromal tumor (GIST) refractory to imatinib, sunitinib, and regorafenib based on the pivotal INVICTUS phase III study.
Li-Ching Lin, Wen-Kuan Huang, Chueh-Chuan Yen, Chueh-Chuan Yen, Ching-Yao Yang, Meng-Ta Sung, Natalie S. M. Wong, Daniel T. T. Chua, Sarah W. M. Lee, Jen-Shi Chen, Chun-Nan Yeh   +10 more
doaj   +1 more source

Development and Validation of a LC‐MS/MS Method for Ripretinib and Its Metabolite: Example of a Journey From Laboratory Bench to Routine Application With a Greenness Assessment [PDF]

Biomedical Chromatography
Joris Guyon, Sarah Djabarouti
exaly   +2 more sources

Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors

Frontiers in Oncology, 2021
BackgroundThe INVICTUS trial assessed the efficacy and safety of ripretinib compared with placebo in the management of advanced gastrointestinal stromal tumors.MethodWe used a Markov model with three health states: progression-free disease, progression ...
Weiting Liao, Weiting Liao, Huiqiong Xu, David Hutton, Qiuji Wu, Qiuji Wu, Kexun Zhou, Kexun Zhou, Hui Luo, Wanting Lei, Wanting Lei, Mingyang Feng, Mingyang Feng, Yang Yang, Yang Yang, Feng Wen, Feng Wen, Qiu Li, Qiu Li   +18 more
doaj   +1 more source

Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review

Frontiers in Pharmacology, 2023
Background: This case report presents two clinical cases of metastatic refractory gastrointestinal stromal tumor (GIST) with treatment history of 6–14 years.
Yefan Zhang, Zhen Huang
doaj   +1 more source